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Background: Vitamin K antagonists are drugs that are widely prescribed around the world and their use
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interindividual variability has been observed in dosage requirements to reach the desired anticoagula-
tion range that could be due to environmental and genetic factors. Studies suggest that ethnicity
inﬂuences coumarin response, supporting the observed differences in dose requirements across various
populations. Studies using mitochondrial DNA (mtDNA) markers have suggested that the Chilean
population has a predominantly Amerindian genetic pool.
Objective: To evaluate the inﬂuence of ethnicity, deﬁned by the presence of Amerindian mtDNA
haplogroups, on the variability in therapeutic response to warfarin in the Chilean population.
Methods: A total of 191 patients treated with warfarin were included in this study. Analysis of the
mitochondrial genome for detecting the presence of Amerindian mtDNA haplogroups was performed
using polymerase chain reaction and polymerase chain reaction restriction fragment length poly-
morphism techniques. The evaluation of warfarin requirements according to each haplogroup was
performed by ANOVA with a 95% CI and assuming statistical signiﬁcance at P o 0.05.
Results: Based on the presence of an mtDNA haplogroup, 91% of the Chilean population had an
Amerindian background. There were no signiﬁcant differences in warfarin dosage requirements among
the different Amerindian haplogroups (P ¼ 0.083).
Conclusions: The presence of Amerindian mtDNA haplogroup does not inﬂuence warfarin dosage
requirements in the Chilean population.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Anticoagulant therapy has improved the prognosis of patients
with a variety of conditions, including prevention and/or treat-
ment of venous thrombosis, pulmonary embolism, and throm-
boembolic complications associated with atrial ﬁbrillation and
mechanical prosthetic heart valves. However, there is wide inter-
individual variability in dose requirements to achieve the desired
anticoagulation range. A variety of both genetic and environmental
factors contribute to this phenomenon. These include bodyInc. This is an open access article u
e Clinical and Immunohema-
0000 Chile.weight; age; vitamin K intake; drug interactions; allelic variants
in cytochrome P450 2C9 and vitamin K epoxide reductase com-
plex, subunit 1 (VKORC1); and ethnicity. Several studies have
shown the inﬂuence of cytochrome P450 2C9 and VKORC1
variability in dosage requirements, explaining a signiﬁcant pro-
portion of variation in drug response.1 In Latin American popula-
tions, there is little evidence regarding the frequency of occurrence
of the polymorphisms and variability in the response to oral
anticoagulant therapy. Guzman et al2 provide some background
in the Chilean population when they describe the frequency of
variant VKORC1 1639 G4A, associating with lower requirements
of warfarin, but this association was not observed for genotype
CYP2C9*2. In addition, factors such as age and body weight
independently inﬂuence dose requirements. Furthermore, severalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical and demographic characteristics of Chilean patients treated with warfarin.
Characteristic Men (n ¼ 77) Women (n ¼ 114)
Age, y* 65 (13.0) 66 (13.4)
Height, m* 1.70 (0.0) 1.56 (0.0)
Weight, kg* 79.6 (15.3) 68 (14.2)
Hypertension† 47 (61) 66 (57.9)
Diabetes mellitus† 11 (14,2) 10 (8.7)
Dyslipidemia† 12 (15.5) 26 (22.8)
n Values are given as mean (SD).
† Values are given as n (%).
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inﬂuence the dosage requirements of the antagonists of vitamin K.
A clear example of this is the lower requirements of coumarin in
Asian patients (between 30% and 40%) compared with white
populations,3 a factor that could inﬂuence dose requirements of
antagonists of vitamin K.4 Because of the value that has been given
to ethnicity as a factor that might inﬂuence dosage requirements
of coumarin, mitochondrial DNA (mtDNA) is an appropriate tool to
assess this variable, given its unique features. It has a high rate of
variation in sequence (5–10 times greater than that in nuclear
DNA) and it behaves as haploid gene inheritance via maternal
parent over generations and not does not undergo genetic recom-
bination. Its sequence has been completely known since 1981; it
comprises 16,569 base pairs in 37 gene segments. The mtDNA
noncoding is concentrated in the area called loop D, with approx-
imately 1,100 base pairs, which shows a high degree of poly-
morphism in sequence.5,6
Available scientiﬁc evidence suggests that ethnicity is a deter-
mining factor in oral anticoagulant dosage requirements.7 For
example, Asian populations show requirements between 30%
and 40% lower than white populations, whereas African popula-
tions require signiﬁcantly higher dosages than white populations.8
Studies on population genetics show that the Chilean popula-
tion has a mainly Amerindian genetic background, determined by
using mitochondrial genome markers named Amerindian mtDNA
haplogroups.9 Interestingly, in a recent study conducted on
patients treated with atorvastatin, a high frequency of Amerindian
mtDNA haplogroups was described, showing that haplogroup B
individuals had higher levels of total cholesterol after treatment,10
suggesting that the presence of this mitochondrial genome marker
may deﬁne a lower response to treatment using this lipid-
lowering drug.
According to the evidence that shows the mainly Amerindian
component of the Chilean population and the absence of evidence
that shows the inﬂuence of ethnicity on warfarin response in the
Amerindian population, the aim of our study was to evaluate the
potential association between the presence of Amerindian mtDNA
haplogroups and the variability in warfarin dosage requirements.Table 2
Amerindian mitochondrial DNA haplogroup frequency in patients treated with
warfarin.
Patient
Haplogroup n %
A 14 7.3
B 60 31.4
C 56 29.3
D 44 23.1
NA 17 8.9
Total 191 100
NA ¼ Not Amerindian.Materials and Methods
Population under study
A total of 191 patients older than age 18 years (77 men with
a mean [SD] age of 65 [13] years and 114 women with a mean [SD]
age of 66 [13] years) and being treated at 2 medical centers in the
cities of Santiago and Temuco, Chile, were included in the study.
The group was patients receiving oral anticoagulant treatment
using warfarin with a low international normalized ratio (between
2 and 3) in at least the previous 2 medical checks. Patients younger
than age 18 years and patients with chronic liver disease were
excluded from the study.All patients included in the study signed an informed consent
form, in accordance with the basic criteria for biomedical research
listed in the Declaration of Helsinki. After signing the informed
consent form, each patient was surveyed to gather relevant clinical
epidemiologic information for the study, as well as to measure
anthropometric parameters such as weight and size to calculate
body mass index.
Amerindian mtDNA haplogroup characterization
Venous blood anticoagulated with EDTA was extracted using
standard methods and the genomic DNA was extracted using
whole blood using the standardized methodology described by
Salazar et al.11
The Amerindian mtDNA haplogroup characterization was con-
ducted in accordance with the method described.12 Ampliﬁcation
reactions were carried out in a ﬁnal volume of 25 μL with 50 ng
genomic DNA, 100 mM of each primer, 200 mM of each of the
4 deoxyribonucleotides, 1 unit of Taq DNA polymerase, and
polymerase chain reaction buffer (50 mM potassium chloride,
2 mM magnesium chloride, 20 mM ammonium sulfate, and 75
mM Tris-hydrogen chloride; pH 9.0). To determine presence or
absence of the 3 polymorphic restriction sites typical in the
haplogroups A, C, and D of the Amerindian population, digestion
with speciﬁc endonucleases Hae III, Hinc II, and Alu I, respectively,
was conducted.
Finally, the restriction fragments were evaluated by electro-
phoresis in 3% agarose gel stained with GelRed (Biotium Inc,
Hayward, California). Regarding the marker that deﬁnes the B
haplogroup and consists of deleting 1 of the 2 9-base pair
repetitions located in the V intergenic region, visualization was
conducted by electrophoresis in 3% agarose gel directly from the
polymerase chain reaction products obtained. All the gels were
analyzed by 2 people and 20% of the analyses were randomly
repeated for internal control measures.
Statistical Analysis
Amerindian mtDNA haplogroup frequencies were estimated/
calculated directly. To evaluate the differences in warfarin dosage
requirements considering the presence of an Amerindian mtDNA
haplogroup, an ANOVA test was conducted, with a 95% CI and
considering a statistical signiﬁcance value of P o 0.05.Results
Clinical and demographic characteristics of the patients
included in this study are shown in Table 1. The mean age of the
patients evaluated was similar between men and women, at 66
years and 65 years, respectively. Also it should be noted that of the
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Fig. Warfarin (Acenocoumarol) dosage according to Amerindian mitochondrial
DNA haplogroups in Chilean patients treated with an oral anticoagulant. The
horizontal line shows the mean, the box covers the percentiles 25% to 75%, and the
interquartile range. The vertical line above and below the boxes shows the
minimum and maximum values. Each atypical value is shown inside a circle. The
warfarin dosages were not signiﬁcantly different among the Amerindian mitochon-
drial DNA haplogroups.
V. Subiabre et al. / Current Therapeutic Research 77 (2015) 31–34 33surveyed chronic diseases the most predominant in both groups
was high blood pressure.
Frequency distribution Amerindian haplogroups in patients
treated with warfarin is shown in Table 2. In general terms, the
most prevalent haplogroups—B and C—are found in 31% and 29.3%
of the population, respectively; 91% of the population included in
this study showed 1 of the 4 Amerindian mtDNA haplogroups
described.
Warfarin dosage requirements according to the presence of the
different Amerindian mtDNA haplogroups are shown in the
Figure. Results show that there were no signiﬁcant differences in
warfarin dosage requirements according to the presence of 1 of the
4 Amerindian haplogroups analyzed (P ¼ 0.083).Discussion
Coumarins are widely prescribed around the world, showing a
signiﬁcant variability in therapeutic response as a consequence of
genetic and environmental factors. In our study, we evaluated theTable 3
Allele frequency of single-nucleotide polymorphism and haplotypes in the VKORC1 gen
Variant Population
VKORC1 -1639 G4A rs17878363 African American
Asian
White
Hispanic
Chilean
VKORC1 1173 C4T rs9934438 Asian
European
African
Group A Haplotype (H1, H2) European
African
Asian
Group B Haplotype (H7, H8, H9) European
Africana
Asianpotential inﬂuence of ethnicity, deﬁned by population markers of
the mitochondrial genome, on warfarin dosage requirements in
Chilean patients being treated at 2 public hospitals in the cities of
Santiago and Temuco.
Results show that the Amerindian component is predominant
in the population that was included in our study, which correlates
with previous data that show a high frequency of Amerindian
mtDNA haplogroups in Chile.10,12,13 Furthermore, the distribution
of mtDNA haplogroups in the population is not homogenous; the
frequency of distribution of haplogroups C and D progressively
increases toward the south of the country.
When we evaluated the warfarin dosage requirements of any of
the Amerindian haplogroups, no signiﬁcant differences in dosage
requirements among the different Amerindian haplogroups was
observed. In this sense, the presence of any Amerindian mtDNA
haplogroup does not independently inﬂuence warfarin dosage
requirements in the Chilean population. Ours is the ﬁrst study to
evaluate the potential association between the presence of mtDNA
haplogroups and therapeutic response to coumarins in a popula-
tion with an Amerindian genetic background.
Although our results show that the presence of a speciﬁc ethnic
marker of the mitochondrial genome does not inﬂuence warfarin
dosage requirements in the Chilean population, they do suggest
that ethnicity could deﬁne different frequencies for certain poly-
morphisms, which would at least partly explain the variability in
vitamin K antagonist requirements observed in various popula-
tions around the world.
Recently, Scott et al14 provided evidence of the global difference
in the frequency of variants in VKORC1, showing a signiﬁcant
difference among the populations studied (P o 0.0001). Similarly,
in a study that included individuals from various ethnic back-
grounds, the allele frequency of the VKORC1 -1639 G4A variant
was 0.108, 0.667, 0.406, 0.436, and 0.467 in the African American,
Asian, white, Hispanic, and Jewish populations, respectively.15
Table 3 shows the population differences observed for single-
nucleotide polymorphisms and haplotypes classically described in
the VKORC1 gene.
We have recently shown that the VKORC1 -1639 G4A allele
variant has an increased frequency (0.52) in the Chilean popula-
tion, showing that this genetic marker deﬁnes signiﬁcantly lower
requirements of warfarin.16 Based on this, it is possible to suggest
that the presence of dissimilar variant frequencies that signiﬁ-
cantly inﬂuence coumarin dosage requirements could partly
explain the variability observed in the therapeutic response to
vitamin K antagonists in various populations. In this sense, the
increased frequency of the VKORC1 – 1639 G4A observed in a
population with an Amerindian genetic background could explain
the lower warfarin dosage requirements in the Chilean population.e in different populations around the world.
n Allele frequency Reference
600 0.108 Scott et al14
204 0.667 Scott et al14
212 0.406 Scott et al14
202 0.436 Scott et al14
0.52 Guzmán et al2
132 0.848 Nakai et al18
24 0.958 Geisen et al17
200 0.415 Geisen et al17
23 0.130 Geisen et al17
119 0.37 Rieder et al19
96 0.14 Rieder et al19
120 0.89 Rieder et al19
119 0.58 Rieder et al19
96 0.46 Rieder et al19
120 0.10 Rieder et al19
V. Subiabre et al. / Current Therapeutic Research 77 (2015) 31–3434This could be extrapolated to other Latin American populations
that share this characteristic.Conclusions
Results of our study show that there is an increased frequency
of Amerindian mtDNA haplogroups in the population included in
this study, which shows the predominance of this genetic back-
ground in the Chilean population. However, the variation of the
Amerindian mtDNA haplogroups does not inﬂuence the warfarin
dosage requirements in the group studied.Acknowledgments
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